Brain, Vol. 119, No. 6, 2085-2095, 1996
© 1996 Guarantors of Brain
research-article |
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
1PET Department, Paul Scherrer Institute Villigen 2Institute of Medical Genetics, University of Zurich Villigen 3institute of biomedical Engineering, University and ETH Zurich Villigen 4Department of Neurology, University Hospital Zurich Switzerland 5Servicio de Neurología, Fundación Jiménez Díaz Madrid, Spain 6Department of Neurology, Technical University of Munich Germany
Correspondence to:
Correspondence to: Professor K. L Leenders, PET Department, Paul Scherrer Institute, CH-5232 Villigen, Switzerland
We used PET scans with the tracers [18F]fluorodeoxyglucose (FDG) and [11C]raclopride (RACLO) to study glucose metabolism and dopamine D2 receptor binding in the caudate nucleus and putamen of 18 carriers of the Huntington's disease gene mutation (10 asymptomatic subjects and eight untreated symptomatic Huntington's disease patients in an early disease stage). We also performed MR1 scans and measured the bicaudate ratio (BCR) in the same subjects. Data were compared with those from nine mutation-negative members of Huntington's disease families and separate groups of age matched controls. The PET scans were repeated 1.5–3 years later in six of the asymptomatic gene carriers. Symptomatic Huntington's disease patients showed a marked reduction of FDG and RACLO uptake in the caudate nucleus and putamen and a significant increase of BCR. Asymptomatic mutation carriers revealed significant hypometabolism in the caudate nucleus and putamen. The RACLO binding was significantly decreased in the putamen. Decrements of caudate nucleus tracer uptake, particularly RACLO, correlated significantly with BCR increases in both symptomatic and asymptomatic gene carriers. In asymptomatic carriers, metabolic and receptor binding decreases were also significantly associated with the CAG repeat number but not with the individual's age. Discriminant function analysis correctly classified clinical and genetic status in 24 of 27 subjects on the basis of their striatal PET values (83% sensitivity and 100% specificity). Three asymptomatic mutation carriers were classified/grouped together with mutation-negative subjects, indicating that these individuals had normal striatal RACLO and FDG uptake. Follow-up PET data from gene-positive subjects showed a significant reduction in the mean striatal RACLO binding of 6.3% per year. Striatal glucose metabolism revealed an overall non significant 2.3% decrease per year These data indicate that asymptomatic Huntington's disease mutation carriers may show normal neuronal function for a long period of life. These findings also suggest that it may be possible to predict when an asymptomatic gene carrier will develop clinical symptoms from serial PET measurements of striatal function.
Huntington's disease; PET; MRI; glucose metabolism; dopamine D2 receptors
Received September 14, 1995. Revised May 2, 1996. Accepted July 19, 1996.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease Hum. Mol. Genet., August 15, 2009; 18(16): 3048 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Benchoua, Y. Trioulier, E. Diguet, C. Malgorn, M.-C. Gaillard, N. Dufour, J.-M. Elalouf, S. Krajewski, P. Hantraye, N. Deglon, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II Hum. Mol. Genet., May 15, 2008; 17(10): 1446 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Feigin, C. Tang, Y. Ma, P. Mattis, D. Zgaljardic, M. Guttman, J. S. Paulsen, V. Dhawan, and D. Eidelberg Thalamic metabolism and symptom onset in preclinical Huntington's disease Brain, November 1, 2007; 130(11): 2858 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao and M. I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R115 - R123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Lumsden, T. L. Henshall, S. Dayan, M. T. Lardelli, and R. I. Richards Huntingtin-deficient zebrafish exhibit defects in iron utilization and development Hum. Mol. Genet., August 15, 2007; 16(16): 1905 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Tang, X. Chen, J. Liu, and I. Bezprozvanny Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease J. Neurosci., July 25, 2007; 27(30): 7899 - 7910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. F. Tai, N. Pavese, A. Gerhard, S. J. Tabrizi, R. A. Barker, D. J. Brooks, and P. Piccini Microglial activation in presymptomatic Huntington's disease gene carriers Brain, July 1, 2007; 130(7): 1759 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Powers, T. O. Videen, J. Markham, L. McGee-Minnich, J. V. Antenor-Dorsey, T. Hershey, and J. S. Perlmutter Selective defect of in vivo glycolysis in early Huntington's disease striatum PNAS, February 20, 2007; 104(8): 2945 - 2949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cyr, T. D. Sotnikova, R. R. Gainetdinov, and M. G. Caron Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin FASEB J, December 1, 2006; 20(14): 2541 - 2543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ciarmiello, M. Cannella, S. Lastoria, M. Simonelli, L. Frati, D. C. Rubinsztein, and F. Squitieri Brain White-Matter Volume Loss and Glucose Hypometabolism Precede the Clinical Symptoms of Huntington's Disease J. Nucl. Med., February 1, 2006; 47(2): 215 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.C.H. van Oostrom, R. P. Maguire, C. C. Verschuuren-Bemelmans, L. Veenma-van der Duin, J. Pruim, R. A.C. Roos, and K. L. Leenders Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease Neurology, September 27, 2005; 65(6): 941 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription PNAS, January 4, 2005; 102(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Aylward, B. F. Sparks, K. M. Field, V. Yallapragada, B. D. Shpritz, A. Rosenblatt, J. Brandt, L. M. Gourley, K. Liang, H. Zhou, et al. Onset and rate of striatal atrophy in preclinical Huntington disease Neurology, July 13, 2004; 63(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y F Tai and P Piccini Applications of positron emission tomography (PET) in neurology J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gaura, A.-C. Bachoud-Levi, M.-J. Ribeiro, J.-P. Nguyen, V. Frouin, S. Baudic, P. Brugieres, J.-F. Mangin, M.-F. Boisse, S. Palfi, et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients Brain, January 1, 2004; 127(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pavese, T. C. Andrews, D. J. Brooks, A. K. Ho, A. E. Rosser, R. A. Barker, T. W. Robbins, B. J. Sahakian, S. B. Dunnett, and P. Piccini Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study Brain, May 1, 2003; 126(5): 1127 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Squitieri, C. Gellera, M. Cannella, C. Mariotti, G. Cislaghi, D. C. Rubinsztein, E. W. Almqvist, D. Turner, A.-C. Bachoud-Levi, S. A. Simpson, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course Brain, April 1, 2003; 126(4): 946 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Duan, Z. Guo, H. Jiang, M. Ware, X.-J. Li, and M. P. Mattson Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice PNAS, March 4, 2003; 100(5): 2911 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. de Almeida, C. A. Ross, D. Zala, P. Aebischer, and N. Deglon Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length J. Neurosci., May 1, 2002; 22(9): 3473 - 3483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Feigin, K. L. Leenders, J. R. Moeller, J. Missimer, G. Kuenig, P. Spetsieris, A. Antonini, and D. Eidelberg Metabolic Network Abnormalities in Early Huntington's Disease: An [18F]FDG PET Study J. Nucl. Med., November 1, 2001; 42(11): 1591 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Paulsen, H. Zhao, J. C. Stout, R. R. Brinkman, M. Guttman, C. A. Ross, P. Como, C. Manning, M. R. Hayden, and I. Shoulson Clinical markers of early disease in persons near onset of Huntington's disease Neurology, August 28, 2001; 57(4): 658 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sanchez-Pernaute, G. Kunig, A. del Barrio Alba, J. G. de Yebenes, P. Vontobel, and K. L. Leenders Bradykinesia in early Huntington's disease Neurology, January 11, 2000; 54(1): 119 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Andrews, R. A. Weeks, N. Turjanski, R. N. Gunn, L. H. A. Watkins, B. Sahakian, J. R. Hodges, A. E. Rosser, N. W. Wood, and D. J. Brooks Huntington's disease progression: PET and clinical observations Brain, December 1, 1999; 122(12): 2353 - 2363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Reynolds, R. J. Carter, and A. J. Morton Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntington's Disease J. Neurosci., December 1, 1998; 18(23): 10116 - 10127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Litvan, J. S. Paulsen, M. S. Mega, and J. L. Cummings Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders Arch Neurol, October 1, 1998; 55(10): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-w. Soong and R.-s. Liu Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease J. Neurol. Neurosurg. Psychiatry, April 1, 1998; 64(4): 499 - 504. [Abstract] [Full Text] [PDF]
|
|